1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CK Life Sciences Int'l., (Holdings) Inc.
  6. Summary
    775   KYG2176J1058

CK LIFE SCIENCES INT'L., (HOLDINGS) INC.

(775)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-08-15 am EDT
0.7600 HKD   +1.33%
08/02CK Life Sciences' H1 Profit Down 35%
MT
08/02CK Life Sciences Int'l., Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/26CK Life Sciences Investors Acquire Stake in Pharus for $5.5 Million Each
MT
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
08/09/2022 08/10/2022 08/11/2022 08/12/2022 08/15/2022 Date
0.76(c) 0.75(c) 0.75(c) 0.75(c) 0.76 Last
4 504 000 8 780 000 6 252 000 2 764 000 2 132 000 Volume
0.00% -1.32% 0.00% 0.00% +1.33% Change
More quotes
Estimated financial data (e)
Sales 2020 4 943 M 631 M 631 M
Net income 2020 125 M 16,0 M 16,0 M
Net Debt 2020 5 219 M 666 M 666 M
P/E ratio 2020 67,7x
Yield 2020 1,14%
Sales 2021 5 402 M 689 M 689 M
Net income 2021 163 M 20,8 M 20,8 M
Net Debt 2021 5 311 M 677 M 677 M
P/E ratio 2021 43,8x
Yield 2021 1,35%
Capitalization 7 208 M 920 M 920 M
EV / Sales 2020 2,77x
EV / Sales 2021 2,30x
Nbr of Employees 1 829
Free-Float 25,0%
More Financials
Company
CK Life Sciences Intl (Holdings) Inc is an investment holding company principally engaged in the development and sales of healthcare products. The Company operates through two segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its... 
Sector
Food Processing
Calendar
03/21Earnings Release
More about the company
All news about CK LIFE SCIENCES INT'L., (HOLDINGS) INC.
08/02CK Life Sciences' H1 Profit Down 35%
MT
08/02CK Life Sciences Int'l., Inc. Reports Earnings Results for the Half Year Ended June 30,..
CI
07/26CK Life Sciences Investors Acquire Stake in Pharus for $5.5 Million Each
MT
05/20CK LIFE SCIENCES INT'L., (HOLDINGS) : Ex-dividend day for final dividend
FA
03/15CK Life Sciences Int'l., Inc. Announces Ordinary Final Cash Dividend for the Year Ended..
CI
03/15CK Life Sciences Int'l., Inc. Reports Earnings Results for the Full Year Ended December..
CI
2021CK HUTCHISON : CK Asset profits rise in H1
RE
2021CK LIFE SCIENCES 'L : Posts Higher Profit, Revenue in H1
MT
2021Ck Life Sciences Int'l., Holdings Inc. Reports Earnings Results for the Half Year Ended..
CI
2021CK LIFE SCIENCES INT'L., (HOLDINGS) : Ex-dividend day for final dividend
FA
2021CK LIFE SCIENCES 'L : Proposals for Election of Directors at the AGM, General Mandates to ..
PU
2021CK LIFE SCIENCES 'L : ' Profit Slumps 31% in 2020 as Pandemic Hits
MT
2021CK LIFE SCIENCES 'L : Annual results for 2020
PU
2021Ck Life Sciences Int'l., Inc. Recommends Final Dividend for the Year Ended 31 December ..
CI
2021Ck Life Sciences Int'l., Holdings Inc. Reports Earnings Results for the Full Year Ended..
CI
More news
News in other languages on CK LIFE SCIENCES INT'L., (HOLDINGS) INC.
08/02Le bénéfice de CK Life Sciences au premier semestre est en baisse de 35 %.
08/02CK Life Sciences Int'l., (Holdings) Inc. annonce ses résultats pour le semestre se term..
07/26Les investisseurs de CK Life Sciences acquièrent une participation dans Pharus pour 5,5..
03/15CK Life Sciences Int'l., (Holdings) Inc. annonce un dividende final ordinaire en espèce..
03/15CK Life Sciences Int'l., (Holdings) Inc. annonce ses résultats pour l'année complète se..
More news
Chart CK LIFE SCIENCES INT'L., (HOLDINGS) INC.
Duration : Period :
CK Life Sciences Int'l., (Holdings) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CK LIFE SCIENCES INT'L., (HOLDINGS) INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers and Directors
Ying Choi Yu Chief Operating Officer & Vice President
Hing Lam Kam President & Executive Director
Yiu Leung Mo Chief Financial Officer
Tzar Kuoi Li Chairman
Kean Meng Toh Executive Director & Chief Scientific Officer
Sector and Competitors